MedPath

D-Lung: An Analytics Platform for Lung Cancer Based on Deep Learning Technology

Completed
Conditions
Lung Cancer
Registration Number
NCT04036903
Lead Sponsor
Chinese University of Hong Kong
Brief Summary

Lung cancer is one of main cause of cancer death in worldwide, characterized of low 5-year survival rate of less than 20%. Pulmonary nodule is considered as the typical imaging manifestation in early stage of lung cancer. The National Lung Screen Trial has demonstrated that the mortality rates could decline greatly, by the utility of low-dose helical computed tomography for screen of pulmonary nodules. Thus, automatic detection, diagnosis and management of pulmonary nodules, play the vital roles in computer-aided lung cancer screening and early intervention.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
130
Inclusion Criteria
  • Subjects with suspicious lung nodules.
  • Thin-layer thoracic CT and pathology examination have been performed for suspicious lung nodules.
Exclusion Criteria
  • Subjects with accompanied lesions on CT images that may interfere to lung nodules analysis

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
accuracy2 years

proportion of true results(both true positives and true negatives) among whole instances

sensitivity2 years

true positive rate in percentage(%) derived by ROC analysis

specificity2 years

true negative rate in percentage (%) derived by ROC analysis

area under curve (AUC)2 years

area under ROC curve in percentage (%)

Secondary Outcome Measures
NameTimeMethod
average number of false positives per scan (FPs/scan)2 years

FPs/scan in number (N) based on free-response receiver operating characteristic (FROC) analysis

competition performance metric (CPM)2 years

Competitive performance metric (CPM) is a criterion used for CAD system evaluation. Based on FROC paradigm, CPM score is computed as an average sensitivity at seven predefined average false positive rates. CPM score ranges from 0 to 1, with higher CPM score indicating better CAD performance.

Trial Locations

Locations (1)

The Chinese University of Hong Kong, Prince of Wale Hospital

🇭🇰

Hong Kong, Shatin, Hong Kong

© Copyright 2025. All Rights Reserved by MedPath